Compare EDSA & AEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDSA | AEI |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 91.4M |
| IPO Year | N/A | N/A |
| Metric | EDSA | AEI |
|---|---|---|
| Price | $1.46 | $2.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $13.00 | N/A |
| AVG Volume (30 Days) | 31.9K | ★ 37.9K |
| Earning Date | 12-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $12,108,028.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.44 | $0.70 |
| 52 Week High | $4.49 | $4.55 |
| Indicator | EDSA | AEI |
|---|---|---|
| Relative Strength Index (RSI) | 29.73 | 47.62 |
| Support Level | $1.44 | $2.68 |
| Resistance Level | $1.82 | $3.45 |
| Average True Range (ATR) | 0.08 | 0.36 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 11.84 | 21.05 |
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.